Drug Trial Radar · NCT07714668
A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
171
Planned (sponsor's estimate)
Start
Aug 13, 2026
Primary completion
Apr 30, 2028
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.
Conditions
- Ovarian Cancer
- Recurrent Ovarian Cancer
Interventions
SYS6041, bevacizumabDrug
SYS6041: RP2D dose, ivgtt, Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W
SYS6041, carboplatin, bevacizumabDrug
SYS6041: RP2D dose, ivgtt, Q3W Carboplatin: AUC5, ivgtt. Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W
paclitaxel, carboplatin, bevacizumabDrug
Paclitaxel:175mg/m2, ivgtt, Q3W Carboplatin: AUC5, ivgtt. Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W
SYS6041, enlonstobart, bevacizumabDrug
SYS6041: RP2D dose, ivgtt, Q3W Enlonstobart:360mg, ivgtt, Q3W Bevacizumab: 15mg/kg, ivgtt, Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- AEs and SAEsTime frame: Baseline up to 30 days post last dose
- Recommended Phase 2 Dose (RP2D )Time frame: Up to approximately 3 years
- Objective Response Rate (ORR)Time frame: Up to approximately 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.